Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines

Manny D Bacolod1, Paul B Fisher2, Francis Barany1

  • 1Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, United States.

Insights

Predicting cancer drug efficacy is now possible using DNA methylation. CpG methylation models accurately forecast paclitaxel (PTX) and docetaxel (DTX) drug activity, offering new insights into taxane response.

Area of Science:

  • Pharmacogenomics and Computational Biology
  • Cancer Therapeutics and Drug Resistance

Background:

  • Paclitaxel (PTX) and docetaxel (DTX) are vital microtubule-targeting chemotherapeutic agents.
  • Taxane efficacy is influenced by complex factors including apoptosis regulation, microtubule interactions, and drug resistance mechanisms.
  • Predictive biomarkers for taxane response remain crucial for optimizing cancer treatment.

Approach:

  • Developed multi-CpG linear regression models integrating pharmacological and genome-wide molecular profiling data from cancer cell lines.
  • Compared CpG methylation-based models against mRNA expression and mutation-based models for predicting drug activity.

Key Points:

  • CpG methylation models achieved high precision in predicting PTX (R 2=0.985) and DTX (R 2=0.996) activity across diverse cell lines.
  • CpG models demonstrated superior accuracy compared to mRNA/mutation models (PTX R 2=0.830, DTX R 2=0.751).
  • Models highlighted genes involved in apoptosis, mitosis, epigenetic regulation, and novel pathways linked to taxane activity.

Conclusions:

  • DNA methylation at specific CpG sites can accurately predict paclitaxel and docetaxel activity in cancer cell lines.
  • CpG methylation models offer superior predictive performance compared to models based on mRNA expression and mutation data.
  • These findings highlight the potential of epigenetic biomarkers for predicting taxane response and understanding underlying resistance mechanisms.